Management of Desmoid Tumors

Gaya Spolverato; Giulia Capelli; Bernd Kasper; Mrinal Gounder

doi:10.1016/j.soc.2022.03.008

Management of Desmoid Tumors

Surg Oncol Clin N Am. 2022 Jul;31(3):447-458. doi: 10.1016/j.soc.2022.03.008. Epub 2022 May 31.

Authors

Gaya Spolverato¹, Giulia Capelli², Bernd Kasper³, Mrinal Gounder⁴

Affiliations

¹ Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, Padua 35121, Italy. Electronic address: gaya.spolverato@unipd.it.
² Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, Padua 35121, Italy.
³ Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany.
⁴ Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 East 66th Street, BAIC 1075, New York, NY 10065, USA.

PMID: 35715144
DOI: 10.1016/j.soc.2022.03.008

Abstract

The management of desmoid tumors (DT) is shifting toward conservative and patient-tailored strategies. Active surveillance is currently considered the first line of treatment for most DT patients, according to international guidelines. When active treatment is required, several systemic and local treatments are considered. The choice of the first-line systemic therapy and the management of recurrence still represent a therapeutic challenge, for which well-defined and shared guidelines are lacking. Such issues represent the next challenge for The Desmoid Tumor Working Group.

Keywords: Active surveillance; Aggressive fibromatosis; Desmoid tumors; Desmoid-type fibromatosis; Outcomes.

Publication types

Review

MeSH terms

Fibromatosis, Aggressive* / pathology
Fibromatosis, Aggressive* / therapy
Humans